The present invention relates to oleaginous yeast strains overexpressing a hexokinase gene, wherein said strains are capable of accumulating lipids. Methods for obtaining said strains as well as methods for producing lipids are also disclosed.

A method for producing glucose and derivatives thereof by means of biotransformation with a recombinant yeast, which belongs to the technical field of synthetic biology. A construction method comprises any one of the following steps: i, knocking out metabolic pathway-related enzymes of glucose and derivatives thereof in a yeast strain; ii, enhancing or using an activity of synthetic pathway-related enzymes of glucose and derivatives thereof in the yeast strain; and iii, enhancing or using a capability of glucose and derivatives thereof in the yeast strain to enter and exit the yeast. Further provided are a recombinant yeast strain capable of producing glucose or derivatives thereof at a high yield and the use thereof in the conversion of a non-grain low-carbon carbon source. The low-carbon non-grain carbon source synthesized by means of using photoelectrocatalysis or traditional chemical industry is used as a substrate, and rapid preparation of food product raw materials glucose and derivatives thereof from the non-grain carbon source is realized by means of recombinant yeast cells.

The invention is related to materials and methods for production of carminic acid from substrates. The invention provides methods and materials for cell-free bioproduction of carminic acid.

The present invention relates to a process for preparing erythrocytes loaded with one or more substance of pharmaceutical interest. The present invention is also directed to loaded erythrocytes thus obtained and pharmaceutical compositions comprising said population of loaded erythrocytes as well as therapeutic application thereof, in particular in the treatment of Ataxia telangiectasia.

The present disclosure relates to genetically engineered hematopoietic cell/s, specifically, lymphocytes, and more specifically, cells of the T cell lineage or a cell population comprising at least one of the cell/s. The disclosed cells comprises and/or expresses at least one nucleic acid sequence encoding at least one molecule involved directly or indirectly in at least one metabolic pathway. The present disclosure provides compositions, methods and uses of the engineered cells.

This disclosure provides a composition containing a conjugate with a modified insulin molecule. The conjugate has an insulin molecule, which can be insulin or an insulin analog, glucagon, GLP-1, GLP-2 or a GLP-I agonist. The conjugate also contains one or more polymers. Each of the one or more polymers is covalently linked to the insulin molecule. Additionally, each of the one or more polymers is covalently linked to between 0 to 50 copies of a decoy ligand, and to between 0 to 50 copies of a glucose-binding agent, such that the combined total number of glucose-binding agents and decoy ligands covalently linked to each of the one or more polymers is at least 1. The conjugate can reversibly bind to soluble glucose and in which the extent of its glucose-binding controls the extent to which the modified insulin is able to bind to and activate the insulin receptor. Methods of making the conjugate, as well as use of the conjugate in treatment, are also provided.

An anti-cancer formulation is described including a dry liquid dispersible composition of a cellular energy inhibitor admixed with a reactive ingredient and a pharmaceutically acceptable carrier, wherein the cellular energy inhibitor has a structure according to formula I; wherein R is selected from one of OR, N(R).sub.2, C(O)R, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, C6-C12 heteroaryl, H, or an alkali metal, where R is selected from one of H, an alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R, where R is selected from one of H, C1-C6 alkyl, or C6-C12 aryl, and where R is selected from on of H, C1-C20 alkyl or C6-C12 aryl.

The present invention relates to a process for preparing erythrocytes loaded with one or more substance of pharmaceutical interest. The present invention is also directed to loaded erythrocytes thus obtained and pharmaceutical compositions comprising said population of loaded erythrocytes as well as therapeutic application thereof, in particular in the treatment of Ataxia telangiectasia.

Disclosed is an isoform of hexokinase 1 (HK1), namely hexokinase 1b (HK1b), for use as a prognosis marker and as a specific target for use in treatment of cancer.